YY1: A Master Regulator at the Crossroads of Targeted Cancer Therapy - A Commentary

Q: What type of study is this?

This is a Literature Review study.

Junhong Jiang

doi:10.24966/aad-7276/100199

August 18, 2025Addiction & Addictive DisordersOpen Access

YY1: A Master Regulator at the Crossroads of Targeted Cancer Therapy - A Commentary

View Full Paper

Ask AI

Bookmark

Share

Key Points

Downregulation of yy1 significantly correlates with improved drug response in oncogene-addicted cancers, and drug resistance can be mitigated.
The commentary highlights how understanding molecular mechanisms can reshape targeted therapy strategies, providing critical insights into cancer treatment.
YY1's role as a master regulator was analyzed in relation to resistance mechanisms affecting drug efficacy and patient outcomes.
By uncovering yy1's involvement, new approaches to enhance the effectiveness of targeted therapies may be developed.

Implication

Commentary reveals yy1's role in drug resistance in oncogene-addicted cancers, indicating potential therapeutic strategies.

Abstract

Our recent publication entitled “YY1 downregulation underlies therapeutic response to molecular targeted agents” represents a significant advancement in our understanding of the molecular mechanisms governing drug resistance in oncogene-addicted cancers [1].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Junhong Jiang (2025) studied this question.

synapsesocial.com/papers/68af4953ad7bf08b1ead513d https://doi.org/10.24966/aad-7276/100199

View Full Paper

Ask AI

Bookmark

Share

YY1: A Master Regulator at the Crossroads of Targeted Cancer Therapy - A Commentary

Key Points

Implication

Abstract

Discussion

Cite This Study

YY1: A Master Regulator at the Crossroads of Targeted Cancer Therapy - A Commentary

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading